
Neurocrine Biosciences, Inc. – NASDAQ:NBIX
Neurocrine Biosciences stock price today
Neurocrine Biosciences stock price monthly change
Neurocrine Biosciences stock price quarterly change
Neurocrine Biosciences stock price yearly change
Neurocrine Biosciences key metrics
Market Cap | 13.55B |
Enterprise value | N/A |
P/E | 64.51 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 6.67 |
Price/Book | 5.82 |
PEG ratio | 0.90 |
EPS | 3.76 |
Revenue | 1.98B |
EBITDA | 482.3M |
Income | 369.7M |
Revenue Q/Q | 22.57% |
Revenue Y/Y | 23.99% |
Profit margin | 10.38% |
Oper. margin | 16.73% |
Gross margin | 98.44% |
EBIT margin | 16.73% |
EBITDA margin | 24.33% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNeurocrine Biosciences stock price history
Neurocrine Biosciences stock forecast
Neurocrine Biosciences financial statements
$150.14
Potential upside: 13.05%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 452.7M | 95.5M | 21.1% |
---|---|---|---|
Sep 2023 | 498.8M | 83.1M | 16.66% |
Dec 2023 | 515.2M | 147.7M | 28.67% |
Mar 2024 | 515.29M | 43.4M | 8.42% |
Jun 2023 | 2613100000 | 760.1M | 29.09% |
---|---|---|---|
Sep 2023 | 2848200000 | 846.1M | 29.71% |
Dec 2023 | 3251400000 | 1.01B | 31.35% |
Mar 2024 | 3472400000 | 1.08B | 31.28% |
Jun 2023 | 179.6M | -125.9M | 2.9M |
---|---|---|---|
Sep 2023 | 212M | -97.3M | 18.8M |
Dec 2023 | 123.5M | -201.8M | 35.4M |
Mar 2024 | 130.3M | -55M | 69.9M |
Neurocrine Biosciences alternative data
Aug 2023 | 1,300 |
---|---|
Sep 2023 | 1,350 |
Oct 2023 | 1,350 |
Nov 2023 | 1,350 |
Dec 2023 | 1,400 |
Jan 2024 | 1,400 |
Feb 2024 | 1,400 |
Mar 2024 | 1,400 |
Apr 2024 | 1,400 |
May 2024 | 1,400 |
Jun 2024 | 1,448 |
Jul 2024 | 1,448 |
Neurocrine Biosciences other data
Period | Buy | Sel |
---|---|---|
Jan 2024 | 0 | 277731 |
Feb 2024 | 0 | 74279 |
Mar 2024 | 0 | 144521 |
Apr 2024 | 0 | 12859 |
May 2024 | 0 | 87358 |
Jul 2024 | 0 | 22863 |
Aug 2024 | 0 | 62964 |
Sep 2024 | 0 | 3461 |
Oct 2024 | 0 | 1295 |
Nov 2024 | 0 | 2331 |
Dec 2024 | 0 | 1091 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Option | DELAET INGRID officer: Chief Regulatory Officer | Non-Qualified Stock Option | 1,091 | $79.02 | $86,211 | ||
Sale | DELAET INGRID officer: Chief Regulatory Officer | Common Stock | 1,091 | $135 | $147,285 | ||
Option | DELAET INGRID officer: Chief Regulatory Officer | Common Stock | 1,091 | $79.02 | $86,211 | ||
Option | ONYIA JUDE officer: Chief Scientific Officer | Common Stock | 4,426 | N/A | N/A | ||
Sale | ONYIA JUDE officer: Chief Scientific Officer | Common Stock | 2,331 | $126.29 | $294,373 | ||
Option | ONYIA JUDE officer: Chief Scientific Officer | Restricted Stock Unit | 4,426 | N/A | N/A | ||
Option | ROBERTS EIRY officer: Chief Me.. | Common Stock | 1 | $79.02 | $79 | ||
Option | ROBERTS EIRY officer: Chief Me.. | Common Stock | 971 | $102.9 | $99,916 | ||
Option | ROBERTS EIRY officer: Chief Me.. | Common Stock | 1,233 | $81.05 | $99,935 | ||
Option | ROBERTS EIRY officer: Chief Me.. | Common Stock | 5,140 | $77.81 | $399,943 |
Quarter | Transcript |
---|---|
Q1 2024 1 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 7 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 31 Oct 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 1 Aug 2023 | Q2 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Dr. Kevin C. Gorman Ph.D. (1958) Chief Executive Officer & Director | $1,380,000 |
Dr. Eiry Wyn Roberts (1964) Chief Medical Officer | $847,940 |
Mr. Matthew C. Abernethy (1980) Chief Financial Officer | $781,040 |
Mr. Eric S. Benevich (1965) Chief Commercial Officer | $748,830 |
Mr. Kyle W. Gano (1973) Chief Bus. Devel. and Strategy Officer | $711,720 |
Neurocrine Biosciences: Still A Buy After 30% Uplift Since My Last Coverage
Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One
Why Investors Should Watch Teva Despite Regional Risks
Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025
Neurocrine Biosciences: Recent Selloff Has Created A Potential Buying Opportunity
Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart
Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth
Neurocrine Biosciences: Diverse Pipeline, High Margins, And Growth Potential In Biotech
Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth
-
What's the price of Neurocrine Biosciences stock today?
One share of Neurocrine Biosciences stock can currently be purchased for approximately $132.81.
-
When is Neurocrine Biosciences's next earnings date?
Unfortunately, Neurocrine Biosciences's (NBIX) next earnings date is currently unknown.
-
Does Neurocrine Biosciences pay dividends?
No, Neurocrine Biosciences does not pay dividends.
-
How much money does Neurocrine Biosciences make?
Neurocrine Biosciences has a market capitalization of 13.55B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 26.76% to 1.89B US dollars.
-
What is Neurocrine Biosciences's stock symbol?
Neurocrine Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "NBIX".
-
What is Neurocrine Biosciences's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Neurocrine Biosciences?
Shares of Neurocrine Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Neurocrine Biosciences's key executives?
Neurocrine Biosciences's management team includes the following people:
- Dr. Kevin C. Gorman Ph.D. Chief Executive Officer & Director(age: 67, pay: $1,380,000)
- Dr. Eiry Wyn Roberts Chief Medical Officer(age: 61, pay: $847,940)
- Mr. Matthew C. Abernethy Chief Financial Officer(age: 45, pay: $781,040)
- Mr. Eric S. Benevich Chief Commercial Officer(age: 60, pay: $748,830)
- Mr. Kyle W. Gano Chief Bus. Devel. and Strategy Officer(age: 52, pay: $711,720)
-
How many employees does Neurocrine Biosciences have?
As Jul 2024, Neurocrine Biosciences employs 1,448 workers, which is 3% more then previous quarter.
-
When Neurocrine Biosciences went public?
Neurocrine Biosciences, Inc. is publicly traded company for more then 29 years since IPO on 23 May 1996.
-
What is Neurocrine Biosciences's official website?
The official website for Neurocrine Biosciences is neurocrine.com.
-
Where are Neurocrine Biosciences's headquarters?
Neurocrine Biosciences is headquartered at 12780 El Camino Real, San Diego, CA.
-
How can i contact Neurocrine Biosciences?
Neurocrine Biosciences's mailing address is 12780 El Camino Real, San Diego, CA and company can be reached via phone at 858 617 7600.
-
What is Neurocrine Biosciences stock forecast & price target?
Based on 6 Wall Street analysts` predicted price targets for Neurocrine Biosciences in the last 12 months, the avarage price target is $150.14. The average price target represents a 13.05% change from the last price of $132.81.
Neurocrine Biosciences company profile:

Neurocrine Biosciences, Inc.
neurocrine.comNASDAQ
1,700
Drug Manufacturers - Specialty & Generic
Healthcare
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
San Diego, CA 92130
CIK: 0000914475
ISIN: US64125C1099
CUSIP: 64125C109